Phase i study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6882-6890

  Oki, Yasuhiro ^a   Buglio, Daniela ^a   Fanale, Michelle ^a   Fayad, Luis ^a   Copeland, Amanda ^a   Romaguera, Jorge ^a   Kwak, Larry W ^a   Pro, Barbara ^a   De Castro Faria, Silvana ^a   Neelapu, Sattva ^a   Fowler, Nathan ^a   Hagemeister, Fredrick ^a   Zhang, Jiexin ^a   Zhou, Shouhao ^a   Feng, Lei ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; CREATININE; CYTOKINE; EVEROLIMUS; GLUCOSE TRANSPORTER 1; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 5; MAMMALIAN TARGET OF RAPAMYCIN; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; STAT5 PROTEIN; STAT6 PROTEIN; VASCULOTROPIN;

ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD TOXICITY; BODY WEIGHT DISORDER; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPHASIA; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IN VITRO STUDY; INFECTION; INFECTIOUS PNEUMONIA; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; MALE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PRURITUS; QT PROLONGATION; RASH; RHINITIS; RIGOR; SENSORY NEUROPATHY; T CELL LYMPHOMA; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTONE DEACETYLASE INHIBITORS; HODGKIN DISEASE; HUMANS; HYDROXAMIC ACIDS; INDOLES; INTERLEUKIN-5; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84890606231     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1906     Document Type: Article

References (25)

1. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011;8:85-96.
2. Younes A, Berry DA. From drug discovery to biomarker-driven clinical trials in lymphoma. Nat Rev Clin Oncol 2012;9:643-53.
3. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012;30:2197-203.
4. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011;12:1222-8.
5. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631-6.
6. Oki Y, Copeland A, Younes A. Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol 2011;4:245-52.
7. Mahadevan D, Fisher RI. Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1876-84.
8. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012;14:129-38.
9. Johnston PB, Pinter-Brown LC, Rogerio JW, Warsi G, Chau Q, Ram-chandren R. Everolimus (EVE) for relapsed/refractory classical Hodg-kin lymphoma (cHL): Open-label, single-arm, phase II study. J Clin Oncol 30, 2012 (suppl; abstr 8028).
10. Renner C, Zinzani P, Gressin R, Klingbiel D, Dietrich PY, Hitz F, et al. A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012;97:1085-91.
11. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341-7.
12. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hemato-logic malignancies. Clin Cancer Res 2006;12:5165-73. (Pubitemid 44453345)
13. Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci USA 2012;109:6561-5.
14. Lemoine M, Buglio D, Jona A, Derenzini E, Medeiros LJ, Berry DA, et al. The pan-deacetylase inhibitor panobinostat downregulates HIF-1 alpha and VEGF and, synergizes with everolimus in Hodgkin lympho-ma cell lines. Blood 2010;116: abstract 2851.
15. Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J, et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012;119:4017-25.
16. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;112:1424-33.
17. Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 2011;117;2910-7.
18. Buglio D, Mamidipudi V, Khaskhely NM, Brady H, Heise C, Besterman J, et al. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol 2010; 151:387-96.
19. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009;114:2926-35.
20. Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 2008;36:443-50. (Pubitemid 351384743)
21. Deangelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013; 27:1628-36.
22. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86. (Pubitemid 350002966)
23. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
24. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009;115: 2438-46.
25. Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012; 48:1519-24.